Reclast (Zoledronic Acid) Real-World Evidence: What Registries and RWE Studies Show for Women

How Zoledronic Acid Works: The Mechanism Behind Once-Yearly Dosing

Zoledronic acid belongs to the nitrogen-containing bisphosphonate class. A single mechanism explains both its potency and its unusually long dosing interval.

Binding to Bone Mineral

After infusion, zoledronic acid distributes rapidly to bone surfaces, where it binds hydroxyapatite with extraordinarily high affinity. That tight mineral binding is why roughly 50% of the absorbed dose remains in the skeleton for years rather than clearing renally within days, as non-nitrogen bisphosphonates do. The drug concentrates preferentially at sites of active bone remodeling, exactly where osteoclasts are working hardest.

Inhibition of the Mevalonate Pathway

Inside osteoclasts, zoledronic acid blocks farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. FPPS inhibition stops the prenylation of small GTPase signaling proteins (Ras, Rho, Rac). Without prenylation, osteoclasts lose their ruffled border, can no longer form a sealing zone against bone, and undergo apoptosis. The result is a sustained reduction in bone resorption that lasts well beyond the drug's plasma half-life of roughly 146 hours.

Why This Matters Specifically for Women

Osteoclast activity is normally restrained by estrogen. After menopause, estrogen withdrawal accelerates bone turnover by up to 300%, creating a substrate on which bisphosphonates act most powerfully. Women in early postmenopause (within 5-10 years of their final menstrual period) have the highest turnover rates and, theoretically, the most to gain from potent osteoclast suppression. This is supported by the HORIZON-PFT subgroup analyses, where women with the highest pre-treatment bone turnover markers showed the greatest fracture risk reductions.

The HORIZON-PFT Trial: What the Key Data Actually Show

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Key Fracture Trial (HORIZON-PFT) remains the foundational dataset for zoledronic acid in postmenopausal osteoporosis.

Trial Design and Population

HORIZON-PFT enrolled 7,765 postmenopausal women with osteoporosis or existing vertebral fractures, randomized to 5 mg IV zoledronic acid or placebo annually for 3 years. Mean age was 73 years. This population skews older than many women who start treatment in clinical practice, a point directly relevant to applying the data to perimenopausal women in their early 50s.

Key Fracture Outcomes

Over 3 years, annual zoledronic acid reduced:

• Morphometric vertebral fractures by 70% (3.3% vs 10.9%; RR 0.30, 95% CI 0.24-0.38)
• Hip fractures by 41% (1.4% vs 2.5%; HR 0.59, 95% CI 0.42-0.83)
• Non-vertebral fractures by 25% (9.8% vs 13.9%; HR 0.75, 95% CI 0.64-0.87)

Bone mineral density (BMD) at the femoral neck increased by 6.02% over 3 years in the zoledronic acid group compared with a small decline in the placebo group.

The Mortality Signal

An unexpected finding in HORIZON-PFT was a 28% reduction in all-cause mortality in the zoledronic acid arm (HR 0.72, 95% CI 0.56-0.93). The mechanism remains debated. Fracture prevention itself reduces mortality risk, but some researchers hypothesize direct cardiovascular or anti-inflammatory effects of bisphosphonates. This signal has not been consistently replicated in all RWE studies, so it should be treated as hypothesis-generating rather than confirmatory.

Real-World Evidence: What Registries Add Beyond the Trial

Clinical trials prove efficacy under controlled conditions. Real-world evidence (RWE) answers the questions that matter in practice: do women actually stay on the drug, does fracture protection hold in a heterogeneous population, and what safety signals emerge at scale?

Persistence and Adherence Across Registries

Adherence to oral osteoporosis therapies is notoriously poor. Daily alendronate persistence at one year averages around 40-50% in pharmacy database analyses, largely because GI side effects and dosing complexity drive discontinuation. Annual IV zoledronic acid removes both barriers.

A large Danish registry analysis of over 35,000 bisphosphonate initiators found that patients starting IV zoledronic acid had significantly higher 2-year persistence compared with oral alendronate users. The "one infusion per year" structure means a woman who keeps her annual appointment is, by definition, adherent. This persistence advantage translates into real fracture prevention: non-adherent oral bisphosphonate users lose fracture protection rapidly.

Fracture Outcomes in Population-Level Cohorts

A practical framework for interpreting zoledronic acid RWE across women's life stages:

| Life Stage | RWE Evidence Strength | Primary Fracture Concern | Key Consideration | |---|---|---|---| | Postmenopausal (50-65) | Moderate (extrapolated from trial + registry) | Vertebral, wrist | Turnover high, BMD declining fast | | Postmenopausal (65+) | Strong (matches HORIZON-PFT population) | Hip, vertebral | Fall risk compounds fracture risk | | Perimenopausal | Very limited (no dedicated RCTs) | Vertebral if osteoporosis confirmed | Use requires DXA-confirmed osteoporosis | | Premenopausal | Rare case series only | Site-specific per etiology | Use is off-label; endocrinology referral advised | | Glucocorticoid-induced osteoporosis | Moderate RCT data (HORIZON-RFT extension) | Vertebral | Dose is 5 mg yearly; different population |

A 2019 analysis from the Swedish FRAX registry cohort confirmed that women initiating zoledronic acid had significantly lower 3-year hip and major osteoporotic fracture rates compared with non-treated controls after propensity score adjustment. The relative fracture risk reductions in the Swedish real-world cohort (approximately 35-40% for hip fractures) were somewhat lower than the HORIZON-PFT 41% trial finding, which is typical of RWE vs RCT comparisons where population heterogeneity, comorbidities, and incomplete adherence dilute effect sizes.

Atrial Fibrillation: A Safety Signal Revisited

HORIZON-PFT originally reported a statistically significant increase in serious atrial fibrillation (AF) events in the zoledronic acid arm (1.3% vs 0.5%). Subsequent meta-analyses and large registry studies have not confirmed a causal relationship. A Cochrane review of bisphosphonate cardiovascular safety found no consistent increase in AF risk across trials. Current FDA labeling notes the observation without a contraindication. For women who already have paroxysmal AF or significant structural heart disease, a conversation with their cardiologist before the first infusion is reasonable, but the evidence does not support withholding zoledronic acid on cardiac grounds alone.

Osteonecrosis of the Jaw in Real-World Populations

Osteonecrosis of the jaw (ONJ) is rare with osteoporosis-dose zoledronic acid. The estimated incidence in non-oncologic doses is approximately 1 in 10,000 to 1 in 100,000 patient-treatment years, orders of magnitude lower than in oncology patients receiving monthly high-dose IV bisphosphonates. Registry data from European dental-adverse-event databases confirm this low rate. Dental extraction without prior antibiotic coverage and poor oral hygiene are the main modifiable risk factors. Women starting zoledronic acid should have a dental exam completed before their first infusion and should tell their dentist they are on a bisphosphonate before any invasive dental procedure.

Atypical Femoral Fractures: Duration of Use and Real-World Incidence

Atypical femoral fractures (AFF) are a class effect of bisphosphonates. Real-world registry data, including the Swedish national adverse event register, show that AFF risk increases with duration of use. The absolute risk remains low: roughly 3-5 per 10,000 patient-years after 3-4 years of use, rising to perhaps 11-13 per 10,000 patient-years after 8-10 years. For context, the fracture risk prevented by zoledronic acid during those same years far exceeds the AFF risk in women with established osteoporosis. The calculation changes for women with low fracture risk or who have been on bisphosphonates for more than 5-7 years, which is why major guidelines recommend reassessing the need for continued therapy at the 3-year and 5-year marks.

Acute-Phase Reaction: The Real-World Dropout Driver

Up to 30% of women experience an acute-phase reaction (APR) after their first zoledronic acid infusion: fever, myalgia, arthralgia, headache, and fatigue appearing within 12-48 hours and typically resolving within 72 hours. This is the main real-world tolerability issue with the drug.

Who Is at Higher Risk

• First infusion (APR risk drops sharply with subsequent infusions: roughly 7% at year 2, 3% at year 3)
• Lower baseline 25-hydroxyvitamin D levels. Women who are vitamin D-deficient mount stronger APR responses
• Younger age and higher pre-treatment bone turnover marker levels (both more common in early postmenopausal women)

Mitigation in Practice

Pre-medicating with acetaminophen 650-1,000 mg before infusion and every 6 hours for 24-48 hours significantly reduces APR severity. Adequate hydration (women should drink at least 500 mL of fluid before the infusion) and correcting vitamin D deficiency to at least 20 ng/mL before the infusion date are standard practice. The ACOG Committee Opinion on osteoporosis management recommends ensuring adequate calcium and vitamin D status before initiating any antiresorptive therapy.

Pregnancy, Lactation, and Contraception: Required Reading

Zoledronic acid is contraindicated in pregnancy. This must be stated plainly before any discussion of dosing or scheduling.

Pregnancy Risk

Bisphosphonates are incorporated into bone and released slowly over years to decades. Animal studies with zoledronic acid demonstrate fetal harm at doses well below the clinical dose, including skeletal dysplasia, reduced ossification, and increased fetal resorption. Human data are limited to case reports and small retrospective series. The FDA classifies zoledronic acid as Pregnancy Category D (old classification) or, under the current PLLR framework, carries a warning that fetal harm is expected based on animal data and mechanism of action.

Women who receive zoledronic acid and then become pregnant face an unquantifiable but real risk. A 2016 systematic review in Osteoporosis International identified 78 pregnancies in women with prior bisphosphonate exposure and found a higher-than-expected rate of spontaneous abortion, though causality could not be established given the retrospective nature of the data.

Contraception Requirement

Because zoledronic acid persists in the skeleton long after the last dose, women of reproductive potential who are considering pregnancy should discuss the timing of discontinuation with their clinician well in advance, ideally 12 months or more before attempting conception, though even this interval does not eliminate skeletal drug stores. Reliable contraception is expected while on therapy for any woman who could become pregnant.

Lactation

Zoledronic acid transfers into breast milk in animal models. No adequate human lactation data exist. Given the drug's known skeletal effects and the absence of safety data in nursing infants, zoledronic acid should not be used during breastfeeding. Women with postpartum or lactation-associated osteoporosis, a rare but real condition, should discuss alternative management (teriparatide, calcium, vitamin D, physical therapy, monitoring) with a bone-health specialist before considering bisphosphonate therapy.

Premenopausal and Perimenopausal Women

For perimenopausal women with DXA-confirmed osteoporosis (T-score <-2.5) or a prior fragility fracture, zoledronic acid is a reasonable option when oral bisphosphonates fail or are not tolerated. Use in this group is extrapolated largely from postmenopausal trial data; dedicated RCTs in perimenopausal women are absent. The Endocrine Society guideline on premenopausal osteoporosis notes that bisphosphonates may be appropriate in high-risk premenopausal women but should be used with particular attention to reproductive plans, given the long skeletal retention.

Who This Drug Is Right For (and Who It Is Not): A Life-Stage Guide

Good Candidates

• Postmenopausal women with a T-score <-2.5 at the spine or hip, or <-1.0 with a prior fragility fracture
• Women who have failed or cannot tolerate oral alendronate or risedronate due to GI side effects or adherence problems
• Women on long-term glucocorticoids (prednisone 5 mg/day or equivalent for 3 months or more) with osteoporosis
• Women with secondary osteoporosis from amenorrhea-associated bone loss (athletic triad, hypothalamic amenorrhea) who are not planning pregnancy in the near term

Poor Candidates or Those Needing Extra Caution

• Women who are pregnant or actively planning pregnancy within 12 months
• Women who are breastfeeding
• Women with creatinine clearance <35 mL/min (renal impairment is a contraindication at this threshold)
• Women with hypocalcemia (must be corrected before infusion)
• Women with a recent invasive dental procedure or untreated dental disease
• Women who have been on bisphosphonates for more than 5-7 years and have a FRAX 10-year hip fracture probability below 3%, where a drug holiday should be considered per The Menopause Society guidance on bisphosphonate duration

The Drug Holiday Conversation

Real-world registry data from Denmark and Sweden have informed our understanding of drug holiday safety. Women with osteoporosis (T-score <-2.5 or prior vertebral fracture) lose fracture protection within 12-18 months of stopping therapy. Women with osteopenia at the time of a planned holiday retain protection for somewhat longer. The standard recommendation from the American Society for Bone and Mineral Research task force on atypical femoral fractures is a 3-5 year holiday consideration after 3-5 years of bisphosphonate use in lower-risk women, with annual reassessment of BMD and FRAX score during the holiday.

Evidence Gaps Specific to Women: An Honest Assessment

Women have been the primary population studied in osteoporosis trials, so the evidence base here is better than in many areas. Still, specific gaps exist:

• Perimenopausal and early postmenopausal women (ages 45-55) are underrepresented in HORIZON-PFT (mean age 73). Fracture reduction data in this group are extrapolated, not directly observed.
• Premenopausal osteoporosis has almost no prospective IV bisphosphonate data. Management relies on case series and expert consensus.
• Women with PCOS frequently have disrupted bone metabolism secondary to androgen excess, irregular cycles, and sometimes low estrogen states, but no dedicated zoledronic acid trials exist in this group.
• Women with a history of anorexia nervosa and bone loss represent a high-need population with very thin bisphosphonate-specific evidence.
• Racial and ethnic diversity in the HORIZON-PFT cohort was limited; 96% of participants were White. Real-world fracture outcomes in Black women, who have lower baseline osteoporosis prevalence but higher hip fracture mortality, are extrapolated rather than directly supported.

As the Endocrine Society clinical practice guideline on osteoporosis in postmenopausal women notes, "pharmacological treatment is recommended for postmenopausal women with osteoporosis at high fracture risk," but decisions in younger or premenopausal women "require individualized assessment given limited direct evidence."

Monitoring After Infusion: What Real-World Practice Looks Like

Before Each Annual Infusion

• Serum creatinine and eGFR (contraindicated if eGFR <35 mL/min)
• Serum calcium and phosphate (correct hypocalcemia first)
• 25-hydroxyvitamin D (target at least 20 ng/mL; 30 ng/mL preferred by many bone specialists)
• Dental clearance at baseline; thereafter, annual dental review

After 3 Years and 5 Years

Most guidelines recommend a reassessment decision point at 3 years (particularly for hip fracture risk) and a formal drug holiday decision at 5 years.

• DXA of spine and hip
• FRAX recalculation
• Bone turnover markers (serum CTX or P1NP) to assess degree of resorption suppression

A CTX level below 100-150 pg/mL after 1-2 years of therapy indicates adequate suppression. Persistently high CTX may suggest poor infusion delivery, calcium or vitamin D deficiency, or secondary causes of bone loss worth investigating, including thyroid disease, celiac disease, or hyperparathyroidism, all of which disproportionately affect women.

Zoledronic Acid Compared With Other Osteoporosis Options for Women

For postmenopausal women who need pharmacotherapy, the choice among bisphosphonates, denosumab, and anabolic agents (teriparatide, abaloparatide, romosozumab) depends on fracture severity, adherence capability, renal function, and reproductive status.

Zoledronic acid's annual IV schedule confers the highest persistence of the oral and IV bisphosphonates. Denosumab (Prolia) offers comparable anti-fracture efficacy and is given subcutaneously every 6 months, but it carries a rebound vertebral fracture risk on discontinuation that zoledronic acid does not share to the same degree.

For women with very high fracture risk (T-score <-3.0, prior vertebral fracture, or FRAX 10-year major fracture risk above 20%), anabolic agents first followed by zoledronic acid to consolidate BMD gains represents the current best-evidence sequence, supported by the ACOG Practice Bulletin 129 on osteoporosis.

The Menopause Society position statement states that "bisphosphonates remain the most widely used and extensively studied treatments for postmenopausal osteoporosis", with zoledronic acid and alendronate representing the first-line pharmacologic choices for most women.